| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/15/2003 | CN1098930C GRB3-3 gene, variants and uses thereof |
| 01/15/2003 | CN1098851C New ellipticine achroalkali compounds, process for their preparation and pharmaceutical compositions containing them |
| 01/15/2003 | CN1098849C 噻唑衍生物 Thiazole derivatives |
| 01/15/2003 | CN1098707C Medicinal composition containing algal protein polyose extract and extraction of algal protein polyose |
| 01/15/2003 | CN1098698C Medicine for leukemia and its preparing method |
| 01/15/2003 | CN1098691C Propolis honey and its preparing process |
| 01/15/2003 | CN1098684C Orally administerable pharmaceutical formulations |
| 01/14/2003 | US6506912 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 01/14/2003 | US6506891 Cell surface molecule-induced macrophage activation |
| 01/14/2003 | US6506883 Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use |
| 01/14/2003 | US6506881 Specific for human milk fat globule; complementarity determining region derived from variable domains of mouse monoclonal antibody |
| 01/14/2003 | US6506874 Hypoglycemic agents; obesity, nervous system, cardiovascular, and kidney disorder treatment |
| 01/14/2003 | US6506799 Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and |
| 01/14/2003 | US6506796 Cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of |
| 01/14/2003 | US6506783 A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals and can be used to treat viral infections that comprises a fungicide is disclosed. The particular fungicide used is a benzimidazole derivative |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506773 Hydroxamic and carboxylic acid derivatives |
| 01/14/2003 | US6506770 Antiviral compounds |
| 01/14/2003 | US6506764 Hydroxamic and carboxylic acid derivatives |
| 01/14/2003 | US6506755 Thiazolidinecarboxyl acids |
| 01/14/2003 | US6506744 Benzazepinone-derivatives |
| 01/14/2003 | US6506740 Compounds that can be substituted at the 7, 8, and/or 9 positions and methods for preparing the 4- dedimethylamino tetracycline compounds. Other tetracycline compounds are the 4-dedimethylaminotetracycline derivatives with an oxime |
| 01/14/2003 | US6506739 Compounds possess anti-tumor activities or are capable of being modified to have anti-tumor activities; and this invention relates to the use of the compounds in methods for the treatment of tumors and, especially, for the treatment of |
| 01/14/2003 | US6506735 Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences |
| 01/14/2003 | US6506734 20(S) camptothecin glycoconjugates |
| 01/14/2003 | US6506587 Nucleotide sequences coding enzymatic polypeptide; for use as an antitumor a gents |
| 01/14/2003 | US6506571 Human glutathione-S-transferase |
| 01/14/2003 | US6506555 Use of HIV protease inhibiting compounds |
| 01/14/2003 | US6506414 Homogenizing a tissue in a nondenaturing aqueous solvent to obtain particles; aqueous solvent extraction; separation of solid and liquid; fractionating and purifying; inhibitors of matrix metalloprotease and angiogenesis; antitumor agents |
| 01/14/2003 | US6506411 Anti-angiogenic compositions and methods of use |
| 01/14/2003 | US6506383 Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies |
| 01/14/2003 | US6506364 Administering such as sodium 3-iodo-4-hydroxybenzene sulfonate which is rapidly excreted without significant tissue uptake |
| 01/14/2003 | US6506363 Radioiodinated sulfonated phenols and process therefore |
| 01/14/2003 | CA2246758C Peptidomimetic inhibitors of cathepsin d and plasmepsins i and ii |
| 01/14/2003 | CA2217477C Tricyclic compounds useful for inhibition of farnesyl protein transferase |
| 01/14/2003 | CA2194444C Immunomodulators |
| 01/09/2003 | WO2003003016A1 Diagnostic methods and agents |
| 01/09/2003 | WO2003003011A1 Modification of angiogenesis by targeting protein tyrosine phosphatases |
| 01/09/2003 | WO2003003004A2 Method for identifying compounds the specifically deplete mast cells |
| 01/09/2003 | WO2003002765A2 Methods for the diagnosis of cancer based on the obcam and ntm genes |
| 01/09/2003 | WO2003002764A2 Screening method for identifying cancer therapy-relevant compounds |
| 01/09/2003 | WO2003002722A2 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | WO2003002610A1 Extracellular messengers |
| 01/09/2003 | WO2003002608A1 Humanized antibody against fibroblast growth factor-8 and fragment of the antibody |
| 01/09/2003 | WO2003002607A1 Reducing immunogenicities of immunoglobulins by framework-patching |
| 01/09/2003 | WO2003002598A2 Peptides for use as translocation factors |
| 01/09/2003 | WO2003002596A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 01/09/2003 | WO2003002595A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/09/2003 | WO2003002569A1 Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48 |
| 01/09/2003 | WO2003002568A1 Carbohydrate derivatives |
| 01/09/2003 | WO2003002566A1 Purine derivatives as a2b adenosine receptor antagonists |
| 01/09/2003 | WO2003002565A1 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders |
| 01/09/2003 | WO2003002563A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives |
| 01/09/2003 | WO2003002561A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | WO2003002553A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002549A1 Eurotinone and derivatives thereof, method for the production and use of the same |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002531A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002495A1 Novel treatment of adrenocortical hypersecretion and tumour growth |
| 01/09/2003 | WO2003002203A1 Peptide combination for the treatment of cancer |
| 01/09/2003 | WO2003002202A1 Antitumoral formulations of thioxanthenone |
| 01/09/2003 | WO2003002152A2 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 01/09/2003 | WO2003002144A1 Bispecific antibodies that bind to vegf receptors |
| 01/09/2003 | WO2003002143A1 A novel engineered superantigen for human therapy |
| 01/09/2003 | WO2003002142A1 Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
| 01/09/2003 | WO2003002137A2 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis |
| 01/09/2003 | WO2003002130A1 Fat-binding polymers |
| 01/09/2003 | WO2003002128A1 Methods and compositions for treatment of gastric diseases |
| 01/09/2003 | WO2003002127A1 Use of at least one glycoinhibitor substance |
| 01/09/2003 | WO2003002123A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | WO2003002118A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | WO2003002114A2 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 01/09/2003 | WO2003002113A1 Vitamin c compositions |
| 01/09/2003 | WO2003002110A1 METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D¿2? |
| 01/09/2003 | WO2003002102A1 Sustained release pharmaceutical composition |
| 01/09/2003 | WO2003002092A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 01/09/2003 | WO2003002060A2 Method of treating malignancy associated hypercalcemia using active vitamin d analogues |
| 01/09/2003 | WO2003002058A2 Bone anabolic compounds and methods of use |
| 01/09/2003 | WO2003001984A2 Method and apparatus for the photomodulation of living cells |
| 01/09/2003 | WO2002087612A3 Use of stimulated peripheral blood mononuclear cells for treating cancerous diseases |
| 01/09/2003 | WO2002087587A3 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors |
| 01/09/2003 | WO2002080976A3 Hsa-free formulations of interferon-beta |
| 01/09/2003 | WO2002080901A3 Method for the production of anhydrous, pharmaceutical formulations of xanthogenates |
| 01/09/2003 | WO2002078619A3 Alkynylated single-strand oligonucleotide and uses thereof |
| 01/09/2003 | WO2002078617A3 Materials and methods for treatment of cancer and identification of anti-cancer compounds |
| 01/09/2003 | WO2002076397A3 Telomerase inhibitors and methods of their use |
| 01/09/2003 | WO2002074304A3 Composition containing a gallium (iii) complex and a therapeutically effective cytostatic agent |
| 01/09/2003 | WO2002062777A9 Amino ceramide-like compounds and therapeutic methods of use |
| 01/09/2003 | WO2002059558A3 Means and methods for treatment evaluation |
| 01/09/2003 | WO2002059111A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/09/2003 | WO2002059102A3 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 01/09/2003 | WO2002048092A3 Compounds for altering mitochondrial function and cellular responses |
| 01/09/2003 | WO2002046423A3 Protein derived from the melanin-concentrating hormone (mch), corresponding nucleic acids and their use for preparing medicines |
| 01/09/2003 | WO2002044320A3 Human elongase genes and uses thereof |
| 01/09/2003 | WO2002043756A3 Method for obtaining antigenic aggregates and the use thereof in formulations |
| 01/09/2003 | WO2002043664A3 Reducing cellular damage in the human body |
| 01/09/2003 | WO2002036625A3 Prokineticin polypeptides, related compositions and methods |
| 01/09/2003 | WO2002034236A3 Lipid formulations for target delivery |
| 01/09/2003 | WO2002032953A3 Pregnancy-associated plasma protein-a2 (papp-a2) |